Center for Health Technology Assessment and Pharmacoeconomic Research, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.
AstraZeneca Ltd., Budapest, Hungary.
Int J Public Health. 2023 Mar 30;68:1605635. doi: 10.3389/ijph.2023.1605635. eCollection 2023.
Chronic kidney disease (CKD) implies increased comorbidity burden, disability, and mortality, becoming a significant public health problem worldwide, however, prevalence data are lacking in Hungary. We determined CKD prevalence, stage distribution, comorbidities using estimated glomerular filtration rate (eGFR), albuminuria, and international disease codes in a cohort of healthcare utilizing residents within the catchment area of the University of Pécs, in the County Baranya, Hungary, between 2011 and 2019 by database analysis. The number of laboratory-confirmed and diagnosis-coded CKD patients were compared. Of the total 296,781 subjects of the region, 31.3% had eGFR tests and 6.4% had albuminuria measurements, of whom we identified 13,596 CKD patients (14.0%) based on laboratory thresholds. Distribution by eGFR was presented (G3a: 70%, G3b: 22%, G4: 6%, G5: 2%). Amongst all CKD patients 70.2% had hypertension, 41.5% diabetes, 20.5% heart failure, 9.4% myocardial infarction, 10.5% stroke. Only 28.6% of laboratory-confirmed cases were diagnosis-coded for CKD in 2011-2019. CKD prevalence was 14.0% in a Hungarian subpopulation of healthcare-utilizing subjects in 2011-2019, and substantial under-reporting of CKD was also found.
慢性肾脏病（CKD）意味着合并症负担增加、残疾和死亡率增加，成为全球重大公共卫生问题，但匈牙利缺乏患病率数据。我们通过数据库分析，在 2011 年至 2019 年间，确定了匈牙利巴兰尼亚县佩奇大学（University of Pécs）流域内利用医疗保健的居民队列中 CKD 的患病率、分期分布、使用估算肾小球滤过率（eGFR）、白蛋白尿和国际疾病代码的合并症。比较了实验室确诊和诊断编码 CKD 患者的数量。在该地区的 296781 名受试者中，有 31.3%接受了 eGFR 检测，6.4%接受了白蛋白尿检测，其中我们根据实验室阈值确定了 13596 名 CKD 患者（14.0%）。按 eGFR 分布情况（G3a：70%，G3b：22%，G4：6%，G5：2%）。在所有 CKD 患者中，70.2%有高血压，41.5%有糖尿病，20.5%有心衰，9.4%有心肌梗死，10.5%有中风。在 2011 年至 2019 年期间，只有 28.6%的实验室确诊病例被诊断为 CKD。2011 年至 2019 年，匈牙利利用医疗保健的人群中 CKD 的患病率为 14.0%，同时也发现 CKD 的报告严重不足。
